Clinical Research
corporate_fare

Chong Kun Dang Pharmaceutical Corp.

Address
8 Chungjeong-Ro

Sponsor Overview

assignment
2
sponsored trials
science
0
molecules
location_city
2
research centres
public
2
countries
person_search
2
investigators

Specializations

Immunology and Inflammatory Disease

Chong Kun Dang Pharmaceutical Corp. is active in clinical research for psoriatic arthritis, plaque psoriasis, and other immune-mediated inflammatory disorders. Its funded studies also reflect interest in conditions such as atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease.

  • Psoriatic arthritis
  • Moderate-to-severe plaque psoriasis
  • Atopic dermatitis
  • Asthma
  • Chronic rhinosinusitis with nasal polyposis

The sponsor’s research portfolio includes immune-driven diseases affecting the skin, joints, airways, and gastrointestinal tract.

Gastroenterology

The sponsor funds studies in moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis, indicating a clear therapeutic interest in inflammatory bowel disease and related gastrointestinal immunology.

  • Crohn’s disease
  • Ulcerative colitis
  • Inflammatory bowel disease

These areas align with clinical development focused on chronic intestinal inflammation and immune-mediated digestive disorders.

Biosimilars and Biologic Therapy

Clinical activity includes evaluation of biosimilar and biologic candidates such as risankizumab biosimilar and comparator studies against established monoclonal antibody therapies. This reflects interest in treatment options for autoimmune and inflammatory diseases across multiple therapeutic areas.

  • Risankizumab biosimilar
  • Monoclonal antibody therapies
  • Autoimmune disease

Its research program also includes assessment of immunogenicity, pharmacokinetics, and safety in healthy participants to support biologic development.

Sponsored Trials

Trial Name Country Status
A Phase I, Open-Label, Comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of CKD-706 in Healthy Adult ParticipantsGermany GermanyRecruiting
Comparative Study of Pharmacokinetics, Safety, Tolerability, and Immunogenicity of CKD-704 and Risankizumab in Moderate-to-Severe Inflammatory ConditionsPoland PolandNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 0 total (0% not shared with other sponsors)

This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 2 sites collaborated multiple times

This sponsor has worked with 2 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Immune System Diseases2 trials
    322 other sponsors

Partnered Research Centres

2 centres
location_city
assignment97
Mtz Clinical Research Powered By Pratia
Address
Ul. Gładka 22, 02-172 Warsaw
Learn morearrow_forward
location_city
assignment41
PAREXEL International GmbH
Address
Klinikum Westend Haus 31, Spandauer Damm 130, Charlottenburg, 14050 Berlin
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Chong Kun Dang Pharmaceutical Corp..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.